Navigation Links
3SBio Inc. Announces Unaudited First Quarter 2009 Results
Date:5/19/2009

SHENYANG, China, May 19 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the first quarter ended March 31, 2009.

    First Quarter 2009 Financial Highlights:
    -- Total net revenues increased 23.7% over the first quarter of 2008 to
       RMB68.6 million (US$10.0 million).
    -- Operating income (non-GAAP) for the first quarter of 2009 was
       RMB20.6 million (US$3.0 million), an increase from RMB14.6 million
       (US$2.1 million) for the first quarter of 2008. GAAP operating income
       was RMB20.1 million (US$2.9 million) for the first quarter of 2009, an
       increase from RMB14.2 million (US$2.0 million) for the first quarter of
       2008.
    -- Net income (non-GAAP) for the first quarter of 2009 was RMB21.0 million
       (US$3.1 million), compared to RMB20.2 million (US$2.9 million) for the
       first quarter of 2008. GAAP net income for the quarter was
       RMB15.9 million (US$2.3 million) for the first quarter of 2009,
       compared to GAAP net income of RMB19.8 million (US$2.8 million) for the
       first quarter of 2008.
    -- Earnings per share (non-GAAP) for the first quarter of 2009 were
       RMB0.14 (US$0.02), compared to RMB0.13 (US$0.02) for the first quarter
       of 2008. GAAP earnings per share were RMB0.11 (US$0.02) for the first
       quarter of 2009, compared to GAAP earnings per share of RMB0.13
       (US$0.02) for the first quarter of 2008.

* Please refer to "Non-GAAP Financial Measures: Reconciliation of GAAP to non-GAAP" section below for the definition and rationale of all of the non-GAAP measures. Non-GAAP items for the three-month period ended March 31, 2008 have been included as comparatives to conform to the current year's presentation basis.

    First Quarter 2009 Business Highlights:
    -- EPIAO, the Company's flagship injectable recombinant human
       erythropoietin ("EPO") products, demonstrated resilient growth despite
       a challenging environment, with net revenue from EPIAO rising 21.0%
       over the first quarter of 2008 to RMB42.9 million (US$6.3 million) in
       the first quarter of 2009.
    -- TPIAO net revenue increased 21.3% to RMB18.7 million (US$2.7 million)
       in the first quarter of 2009. TPIAO, the Company's protein-based
       therapeutic recombinant human thrombopoietin ("TPO") products,
       demonstrated its continued success in a slowing economy.
    -- 3SBio continued to work closely with the SFDA to advance the regulatory
       approval of the three new product programs submitted in 2008: 36,000 IU
       dosage formulation of EPIAO, NuLeusin, and TPIAO label extension for
       the treatment of ITP.
    -- Construction continued on schedule on the Company's new EPIAO plant,
       which will support the future growth of EPIAO and serve as the first
       step towards exploring global biosimilar opportunities.

"3SBio had a strong start to 2009, delivering revenue growth and demonstrating the continued acceptance of our keystone EPIAO and TPIAO products in domestic and international markets," commented Dr. Jing Lou, Chief Executive Officer of 3SBio. "Our operating margin was solid and we continued to generate positive cash flow, strengthening our bottom line performance while ensuring 3SBio is in a financial position to pursue synergistic business development opportunities that will positively benefit our company. 3SBio has worked diligently to develop a portfolio of current and future pharmaceutical products, and we remain on track to achieve our 2009 financial and operational objectives."

First Quarter 2009 Unaudited Financial Results

Net revenues. Net revenues increased by 23.7% to RMB68.6 million (US$10.0 million) for the first quarter of 2009 from RMB55.5 million (US$7.9 million) for the same period of 2008. This increase was largely due to continued strength from TPIAO and EPIAO products which increased by 21.3% and 21.0%, respectively, over the same period of 2008, and to a lesser degree by impressive growth from export sales which grew 75.6% and our iron product sales which grew 47.5% over the same period of last year.

The growth in sales from EPIAO was driven in part by an expanded oncology sales force, which continued to perform well. TPIAO remained 3SBio's second largest revenue contributor in the quarter, accounting for 27.3% of total net revenues. Export sales exceeded RMB3.3 million (US$0.5 million), and sales of 3SBio's IV Iron Sucrose rose to RMB2.0 million (US$0.3 million) for the first quarter of 2009.

Gross profit. As a result of continued sales growth from key products despite the economic situation, gross profit increased by 23.8% to RMB62.6 million (US$9.2 million) for the first quarter of 2009 from RMB50.6 million (US$7.2 million) for the same period of 2008. Gross margin increased slightly to 91.3% for the first quarter of 2009 from 91.1% for the first quarter of 2008 and 90.6% for the fourth quarter of 2008.

Operating income. Non-GAAP operating income for the first quarter of 2009 grew 40.7% year-over-year to RMB20.6 million (US$3.0 million). GAAP operating income was RMB20.1 million (US$2.9 million) for the first quarter 2009, an increase of 41.7% from operating income of RMB14.2 million (US$2.0 million) for the same period of 2008.

Operating expenses. Non-GAAP operating expenses were RMB42.1 million (US$6.2 million) for the first quarter of 2009. GAAP operating expenses were RMB42.5 million (US$6.2 million) for the first quarter of 2009, an increase of 16.8% from GAAP operating expenses of RMB36.4 million (US$5.2 million) for the same period of last year. Increase in operating expenses was largely driven by the increased sales & marketing expenses as 3SBio continued necessary marketing efforts.

    -- Research and development ("R&D") cost.  GAAP R&D cost for the first
       quarter of 2009 was RMB2.5 million (US$0.4 million), or 3.6% of net
       revenue, compared to RMB2.8 million (US$0.4 million), or 5.0% of net
       revenue for the same period of last year. The decline in R&D cost for
       the first quarter of 2009 was due to the conclusion of several major
       trials in the last quarter of 2008.
    -- Sales, marketing and distribution expenses. GAAP sales, marketing and
       distribution expenses for the first quarter of 2009 were
       RMB32.9 million (US$4.8 million), compared to RMB25.6 million
       (US$3.7 million) for the same period of last year. This represented a
       slight increase to 48.0% of net revenue for the first quarter of 2009,
       compared to 46.2% of net revenue for the same period of last year. The
       increase was primarily attributable to higher sales activities in
       general, continued investment in building the TPIAO brand and EPIAO
       penetration of the Oncology market.
    -- General and administrative expenses. GAAP general and administrative
       expenses for the first quarter of 2009 were RMB7.1 million
       (US$1.0 million), representing a decrease of 11.3% from general and
       administrative expenses of RMB8.0 million (US$1.1 million) for the same
       period of 2008. This marked a decline to 10.3% of net revenue for the
       first quarter of 2009, compared to 14.4% of net revenue for the first
       quarter of 2008.

* Please refer to "Non-GAAP Financial Measures: Reconciliation of GAAP to Non-GAAP" section below for specific non-GAAP operating expenses measures.

Interest income. The Company recorded net interest income of RMB4.1 million (US$0.6 million) for the first quarter of 2009, as compared RMB7.4 million (US$1.1 million) for the same period in 2008. As experienced last quarter, the decrease in interest income was partially due to the decrease in the prevailing market interest rates in the first quarter of 2009 compared to the same period of last year.

Net income. Non-GAAP net income for the first quarter of 2009 was RMB21.0 million (US$3.1 million), excluding share-based compensation and recognition of an impairment loss of RMB4.6 million (US$0.7 million) on available-for-sale securities. This was comparable to non-GAAP net income of RMB20.2 million (US$2.9 million) for the first quarter of 2008.

GAAP net income was RMB15.9 million (US$2.3 million) for the first quarter 2009, compared to net income of RMB19.8 million (US$2.8 million) for the same period of 2008. GAAP net income was largely impacted by the recognition of an impairment loss on available-for-sale securities. Based on the current market condition and the performance of the available-for-sale securities held by the Company, the Company expects no further impairment losses from the financial instruments currently being held.

Cash and cash equivalents/Time deposits. 3SBio had positive operating cash flows for the first quarter of 2009, and as of March 31, 2009 retained a strong balance sheet with cash, cash equivalents and time deposits of RMB752.3 million (US$110.1 million), an increase from RMB733.0 million (US$107.4 million) as of December 31, 2008 and a slight decline from RMB790.4 million (US$ 112.7 million) as of March 31, 2008.

Full Year 2009 Guidance

Based on current market conditions and visibility provided during the first quarter, the Company maintains its total net revenue target for the full year 2009 of between US$43 million to US$45 million, resulting in a year-over-year increase of approximately 21% to 26%.

Conference Call

3SBio's senior management will host a conference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 8:00 pm (Beijing/Hong Kong) on Wednesday, May 20, 2009. The conference call may be accessed using the dial-in numbers below:

International Toll Dial-In Number: +6567357955

    China (Landline):                  8008190121
    China (Mobile):                    4006208038
    U.K.:                              08082346646
    U.S.:                              18665194004
    Hong Kong:                         800933053
    Conference ID:                     97106460

A telephone replay will be available shortly after the call until May 27, 2009, at:

    International Dial-In Number: +61 2 8235 5000
    U.S Dial-in Number:           +18662145335
    Conference ID:                97106460

A live webcast of the conference call and the replay will be available on the investor relations page of 3SBio's website at http://bbs.3sbio.com/en/News/xinvestors.aspx .

Filing of 20F

3SBio filed its Annual Report on Form 20-F for the year ended December 31, 2008 with the SEC on April 21, 2009. The Company's Form 20-F and complete audited financial statements can be found at http://www.3sbio.com . Hard copy versions of the complete audited financial statements are available free of charge upon request from 3SBio's Investor Relations.

Non-GAAP Financial Measures: Reconciliation of GAAP to non-GAAP

To supplement the Company's financial statements presented in accordance with general accepted accounting principles ("GAAP"), the Company has utilized some non-GAAP financial measures to provide investors and management with supplemental measures that facilitate comparisons of operating performance and trends with prior and future operating performance, and that may not otherwise be apparent on a GAAP basis. These non-GAAP financial measures include operating income and operating expenses before stock based compensation expense, and net income, and earnings per share before stock based compensation expense and recognition of an impairment loss on available-for-sale securities. These measures may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principals, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. These measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures. Please see the attached reconciliation of GAAP to non-GAAP for an explanation of the amounts excluded to arrive at non-GAAP financial measures for the three-month periods ended March 31, 2008 and March 31, 2009.

Statement Regarding Unaudited Financial Information

The unaudited financial information set forth above is preliminary and subject to adjustments and modifications. The audited financial statements and related notes are to be included in our annual report on Form 20-F for the year ending December 31, 2009. Adjustments and modifications to the financial statements may be identified during the course of this audit work, which could result in significant differences from this preliminary unaudited financial information.

Currency Convenience Translation

For the convenience of readers, certain RMB amounts have been translated into US dollars at the rate of RMB6.8329 to US$1.00, the noon buying rate for US dollars in effect on March 31, 2009 for cable transfers of RMB per US dollar as certified for customs purposes by the Federal Reserve Bank of New York. 2008 RMB figures were translated into US dollars at the rate of RMB7.0120 to US$1.00, the noon buying rate for US dollars in effect on March 31, 2008.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com .

Safe Harbor Statement

Certain statements in this release that are not purely historical in nature, including the 2009 full year guidance information, statements contained in "2009 Full Year Guidance" section, management comments and the statements of Dr. Jing Lou, Chief Executive Officer of 3SBio, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon 3SBio management's current expectations, and actual results could differ materially. Among the factors that could cause 3SBio's actual results to differ from what the company currently anticipates may include: competition from other domestic and foreign pharmaceutical companies; the market conditions or pharmaceutical products in China; market acceptance of 3SBio products; hospital or patient demand for our products; 3SBio's ability to expand its production, sales and distribution network and other aspects of its operations; its ability to develop and commercialize additional products or additional indications for existing products; its ability to analyze additional in-licensing opportunities; its ability to effectively protect its intellectual property; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government and changes in the healthcare insurance sector in the PRC; and fluctuations in general economic and business conditions in China. As a result, actual results may differ materially from the forward-looking statements contained herein. For additional information on risk factors identified herein and other risk factors, uncertainties and assumptions that may adversely and materially affect 3SBio's business, financial conditions and results of operations, please refer to the company's filings with the Securities and Exchange Commission at http://www.sec.gov , including information detailed in Item 3.D "Risk Factors" in 3SBio's annual report on Form 20-F for the year ended December 31, 2008, as continually amended and updated. 3SBio undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law.



                          3SBio Inc. and subsidiaries
                      Unaudited consolidated balance sheet
                            (expressed in thousands)

                                         December 31,  March 31,   March 31,
                                              2008        2009        2009
                                               RMB         RMB         US$
    Assets
    Current assets
    Cash and cash equivalents                439,237     302,164     44,222
    Time deposits with financial
     institutions                            293,809     450,098     65,872
    Accounts receivable, less allowance
     for doubtful accounts:
    December 31, 2008 -                      - RMB4,503; March
     31, 2009 -              - RMB4,565 (US$668)             73,767      80,891
11,838
    Inventories                                7,748       8,984      1,315
    Prepaid expenses and other
     receivables                               8,249       7,767      1,137
    Deferred tax assets                        1,802       1,600        234

    Total current assets                     824,612     851,504    124,618

    Available-for-sale securities             26,700      19,758      2,892
    Property, plant and equipment, net        78,185      88,208     12,909
    Lease prepayments                          8,894       8,806      1,289
    Non-current deposits                       8,521       6,723        984
    Intangible assets, net                     5,225       4,950        724
    Deferred tax assets                          781         251         37

    Total assets                             952,918     980,200    143,453

    Liabilities

    Current liabilities

    Accounts payable                           1,939       3,102        454
    Deferred grant income                        374         374         55
    Accrued expenses and other payables       25,273      31,958      4,677
    Income tax payable                         1,256       4,470        654
    Other current liabilities                     57          --         --

    Total current liabilities                 28,899      39,904      5,840

    Deferred grant income                      3,152       3,058        448
    Other liabilities                            472          --         --

    Total liabilities                         32,523      42,962      6,288

    Commitments and contingencies                 --          --         --

    Shareholders' equity

    Share capital -ordinary shares
     US$0.0001 par value, 500,000,000
     shares authorized, 150,586,455
     issued and outstanding as of March
     31, 2009 and 152,099,155 issued and
     outstanding as of December 31, 2008.        121         121         18
    Additional paid-in capital               908,377     908,873    133,014
    Accumulated other comprehensive loss    (102,126)   (101,665)   (14,879)
    Retained earnings                        114,023     129,909     19,012

    To Total shareholders' equity            920,395     937,238    137,165

    Total liabilities and shareholders'
     equity                                  952,918     980,200    143,453



                           3SBio Inc. and subsidiaries
              Unaudited quarterly consolidated statements of income
     (expressed in thousands, except per share , per ADS and other share and
                                    ADS data)
                          Three Months Ended March 31, 2009

                                       GAAP          GAAP       Adjustment
                                        RMB           US$            RMB
    Net Revenues
    EPIAO                              42,910        6,280            --
    TPIAO                              18,710        2,738            --
    Intefen                             1,266          185            --
    Inleusin                              268           39            --
    Iron                                2,046          299            --
    Export                              3,331          487            --
    Others                                 67           10            --

    Total net revenues                 68,598       10,038            --
    Cost of revenues                   (5,999)        (878)           51   (1)

    Gross profit                       62,599        9,160            --

    Operating expenses
    Research and development
     costs                             (2,457)        (360)           70   (1)
    Sales, marketing and
     distribution expenses            (32,949)      (4,822)          134   (1)
    General and administrative
     expenses                          (7,089)      (1,037)          193   (1)

    Total operating expenses          (42,495)      (6,219)

    Operating income                   20,104        2,941

    Other income / (expenses),
     net
    Interest income                     4,072          596            --
    Grant income                           94           14
    Impairment loss on available-
     for-sale Securities               (4,624)        (677)        4,624   (2)
    Others                               (342)         (50)           --
    Total other income /
     (expenses), net                     (800)        (117)

    Income before income tax
     expense                           19,304        2,824            --
    Income tax expense                 (3,418)        (500)

    Net income                         15,886        2,324

    Net income per share
    Basic and diluted (3)                0.11         0.02

    Basic weighted average number
     of shares Outstanding        150,586,455  150,586,455
    Diluted weighted average
     number of shares Outstanding 150,586,455  150,586,455

    Net income per ADS
    Basic and diluted (3)                0.74         0.11

    Basic weighted average number
     of ADSs Outstanding           21,512,351   21,512,351
    Diluted weighted average
     number of ADSs Outstanding    21,512,351   21,512,351


                                     Non-GAAP     Non-GAAP
                                        RMB           US$
    Net Revenues
    EPIAO                              42,910        6,280
    TPIAO                              18,710        2,738
    Intefen                             1,266          185
    Inleusin                              268           39
    Iron                                2,046          299
    Export                              3,331          487
    Others                                 67           10

    Total net revenues                 68,598       10,038
    Cost of revenues                   (5,948)        (870)

    Gross profit                       62,650        9,168

    Operating expenses
    Research and development
     costs                             (2,387)        (349)
    Sales, marketing and
     distribution expenses            (32,815)      (4,802)
    General and administrative
     expenses                          (6,896)      (1,009)

    Total operating expenses          (42,098)      (6,160)

    Operating income                   20,552        3,008

    Other income / (expenses),
     net
    Interest income                     4,072          596
    Grant income                           94           14
    Impairment loss on available-
     for-sale Securities                   --           --
    Others                               (342)         (50)
    Total other income /
     (expenses), net                    3,824          560

    Income before income tax
     expense                           24,376        3,568
    Income tax expense                 (3,418)        (500)

    Net income                         20,958        3,068

    Net income per share
    Basic and diluted (3)                0.14         0.02

    Basic weighted average number
     of shares Outstanding        150,586,455  150,586,455
    Diluted weighted average
     number of shares Outstanding 150,586,455  150,586,455

    Net income per ADS
    Basic and diluted (3)                0.97         0.14

    Basic weighted average number
     of ADSs Outstanding           21,512,351   21,512,351
    Diluted weighted average
     number of ADSs Outstanding    21,512,351   21,512,351

Notes to reconciliation of our GAAP statements of income to our non-GAAP statements of income:

    (1). To exclude share-based compensation expense from its non-GAAP
         measures primarily because they are non-cash expenses that the
         Company does not believe are reflective of ongoing operating results.
    (2). To exclude impairment loss on available-for-sale securities from its
         non-GAAP measures primarily because they are non-cash expenses that
         the Company does not believe are reflective of ongoing operating
         results.
    (3). The options that the Company had granted had no impact on diluted EPS
         for the quarter ended March 31, 2009, because the average market
         price of the Company's common stock during the period was less than
         the price at which the options would have been convertible into the
         Company's common stock. The weighted average exercise price of the
         outstanding options as of March 31, 2009 was $1.10 per share.



                           3SBio Inc. and subsidiaries
              Unaudited quarterly consolidated statements of income
    (expressed in thousands, except per share, per ADS and other share and ADS
                                      data)
                        Three Months Ended March 31,2008

                                        GAAP         GAAP       Adjustment
                                         RMB          US$            RMB
    Net Revenues
    EPIAO                              35,469        5,058            --
    TPIAO                              15,420        2,199            --
    Intefen                             1,084          155            --
    Inleusin                              177           25            --
    Iron                                1,387          198            --
    Export                              1,897          270            --
    Others                                 33            5            --

    Total net revenues                 55,467        7,910            --
    Cost of revenues                   (4,911)        (700)           34   (1)

    Gross profit                       50,556        7,210

    Operating expenses
    Research and development
     costs                             (2,756)        (393)           51   (1)
    Sales, marketing and
     distribution expenses            (25,623)      (3,654)           93   (1)
    General and administrative
     expenses                          (7,994)      (1,140)          245   (1)

    Total operating expenses          (36,373)      (5,187)

    Operating income                   14,183        2,023

    Other income / (expenses),
     net
    Interest income                     7,386        1,053
    Grant income                           93           13
    Others                              1,355          194
    Total other income /
     (expenses), net                    8,834        1,260

    Income before income tax
     expense and minority
     interests                         23,017        3,283
    Income tax expense                 (3,344)        (477)

    Income before minority
     interests                         19,673        2,806
    Minority interests, net of
     tax                                   77           11

    Net income                         19,750        2,817

    Net income per share
    Basic and diluted                    0.13         0.02

    Basic weighted average number
     of shares Outstanding        152,099,155  152,099,155
    Effect of dilutive potential
     shares                             1,634        1,634
    Diluted weighted average
     number of shares Outstanding 152,100,789  152,100,789

    Net income per ADS:
    Basic and diluted                    0.91         0.13

    Basic weighted average number
     of ADSs Outstanding           21,728,451   21,728,451
    Effect of dilutive potential
     ADSs                                 233          233
    Diluted weighted average
     number of ADSs Outstanding    21,728,684   21,728,684


                                      Non-GAAP     Non-GAAP
                                         RMB          US$
    Net Revenues
    EPIAO                              35,469        5,058
    TPIAO                              15,420        2,199
    Intefen                             1,084          155
    Inleusin                              177           25
    Iron                                1,387          198
    Export                              1,897          270
    Others                                 33            5

    Total net revenues                 55,467        7,910
    Cost of revenues                   (4,877)        (696)

    Gross profit                       50,590        7,214

    Operating expenses
    Research and development
     costs                             (2,705)        (386)
    Sales, marketing and
     distribution expenses            (25,530)      (3,641)
    General and administrative
     expenses                          (7,749)      (1,105)

    Total operating expenses          (35,984)      (5,132)

    Operating income                   14,606        2,082

    Other income / (expenses),
     net
    Interest income                     7,386        1,053
    Grant income                           93           13
    Others                              1,355          194
    Total other income /
     (expenses), net                    8,834        1,260

    Income before income tax
     expense and minority
     interests                         23,440        3,343
    Income tax expense                 (3,344)        (477)

    Income before minority
     interests                         20,096        2,866
    Minority interests, net of
     tax                                   77           11

    Net income                         20,173        2,877

    Net income per share
    Basic and diluted                    0.13         0.02

    Basic weighted average number
     of shares Outstanding        152,099,155  152,099,155
    Effect of dilutive potential
     shares                             1,634        1,634
    Diluted weighted average
     number of shares Outstanding 152,100,789  152,100,789

    Net income per ADS:
    Basic and diluted                    0.93         0.13

    Basic weighted average number
     of ADSs Outstanding           21,728,451   21,728,451
    Effect of dilutive potential
     ADSs                                 233          233
    Diluted weighted average
     number of ADSs Outstanding    21,728,684   21,728,684

Notes to reconciliation of our GAAP statements of income to our non-GAAP statements of income:

    (1). To exclude share-based compensation expenses from its non-GAAP
         measures primarily because they are non-cash expenses that the
         Company does not believe are reflective of ongoing operating results.



    For further information, please contact:

    Investor Contact:
    3SBio Inc.
     Bo Tan, CFO
     Tel:   +86-24-2581-1820
     Email: Tanbo@3sbio.com

    Investor Relations (China):
    FD Beijing
     Peter Schmidt
     Tel:   +86-10-8591-1953
     Email: Peter.schmidt@fd.com

    Investor Relations (US):
    FD US
     Evan Smith
     John Capodanno
     Tel: +1-212-850-5600

'/>"/>
SOURCE 3SBio Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. 3SBio Inc. Files for SFDA Approval for TPIAO Label Extension for the Treatment of ITP
2. 3SBio Inc. Announces Filing of Annual Report on Form 20-F
3. 3SBio Inc. to Present at The CIBC World Markets 18th Annual Healthcare Conference
4. Volcano Announces OCT Activities at EuroPCR 2009
5. International Isotopes Inc. Announces First Quarter 2009 Financial Results
6. LodgeNet Healthcare Announces Deployment of Interactive Patient Television System in Oklahoma Heart Hospital
7. Arcadia Resources Announces Sale of Non-Strategic Businesses
8. Fred A. Baughman Jr., MD Announces: Vets Sudden Cardiac Deaths Are Not Suicides or Overdoses
9. Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
10. Life Spine(R) Announces Nationwide Market Introduction of KINETIC(R)-SL Dynamic Anterior Cervical Plating System
11. Psychemedics Corporation Announces Sales & Marketing Agreement With Bupa in UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center ... Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This annual ... the world’s leading providers of cereal and other breakfast foods. Its residents often refer ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology: